SARCULATOR
The predictive tool for sarcoma pathologies
App info
Advertisement
App description
Android App Analysis and Review: SARCULATOR, Developed by DIGITAL FOREST srl. Listed in Medical Category. Current Version Is 2.2.1, Updated On 06/11/2023 . According to users reviews on Google Play: SARCULATOR. Achieved Over 7 thousand Installs. SARCULATOR Currently Has 12 Reviews, Average Rating 4.4 Stars
This app is meant to be used only by physicians and it is not meant to make clinical decisions (the clinical usefulness of the two models has not been tested) but to be used as an informative tool to improve the predictive capability of a physician.Two kinds of predictions are possible:
- RPS: 5-year overall survival (OS) and 5-year disease-free survival (DFS) in primary resected retroperitoneal sarcoma (RPS) patients. .
- STS: 5- and 10-year overall survival (OS) and cumulative incidence of distant metastasis (CCI of DM) in primary resected extremity STS patients.
We are currently offering version 2.2.1. This is our latest, most optimized version. It is suitable for many different devices. Free download directly apk from the Google Play Store or other versions we're hosting. Moreover, you can download without registration and no login required.
We have more than 2000+ available devices for Samsung, Xiaomi, Huawei, Oppo, Vivo, Motorola, LG, Google, OnePlus, Sony, Tablet ... with so many options, it’s easy for you to choose games or software that fit your device.
It can come in handy if there are any country restrictions or any restrictions from the side of your device on the Google App Store.
What's New
Update: new model for patients with primary RPS taking into consideration the improved outcome over time and the case-volume effect.
Aggiornamento: nuovo modello per pazienti con sarcomi primitivi del retroperitoneo che tiene in considerazione del miglioramento della prognosi osservata negli anni recenti e l’effetto del volume del centro.
Aggiornamento: nuovo modello per pazienti con sarcomi primitivi del retroperitoneo che tiene in considerazione del miglioramento della prognosi osservata negli anni recenti e l’effetto del volume del centro.
